- Home
- SMTK vs COCP Comparison
SMTK vs COCP Comparison
Compare SMTK & COCP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- SMTK
- COCP
- Stock Information
- Founded
- SMTK 2009
- COCP 2006
- Country
- SMTK United Kingdom
- COCP United States
- Employees
- SMTK N/A
- COCP N/A
- Industry
- SMTK
- COCP Biotechnology: Pharmaceutical Preparations
- Sector
- SMTK
- COCP Health Care
- Exchange
- SMTK NYSE
- COCP Nasdaq
- Market Cap
- SMTK 13.3M
- COCP 15.7M
- IPO Year
- SMTK N/A
- COCP N/A
- Fundamental
- Price
- SMTK $1.34
- COCP $1.63
- Analyst Decision
- SMTK
- COCP Strong Buy
- Analyst Count
- SMTK 0
- COCP 1
- Target Price
- SMTK N/A
- COCP $7.00
- AVG Volume (30 Days)
- SMTK 98.3K
- COCP 27.4K
- Earning Date
- SMTK 05-13-2025
- COCP 05-15-2025
- Dividend Yield
- SMTK N/A
- COCP N/A
- EPS Growth
- SMTK N/A
- COCP N/A
- EPS
- SMTK N/A
- COCP N/A
- Revenue
- SMTK $105,000.00
- COCP N/A
- Revenue This Year
- SMTK N/A
- COCP N/A
- Revenue Next Year
- SMTK N/A
- COCP N/A
- P/E Ratio
- SMTK N/A
- COCP N/A
- Revenue Growth
- SMTK 854.54
- COCP N/A
- 52 Week Low
- SMTK $1.00
- COCP $1.12
- 52 Week High
- SMTK $8.16
- COCP $3.26
- Technical
- Relative Strength Index (RSI)
- SMTK N/A
- COCP 56.83
- Support Level
- SMTK N/A
- COCP $1.55
- Resistance Level
- SMTK N/A
- COCP $1.81
- Average True Range (ATR)
- SMTK 0.00
- COCP 0.15
- MACD
- SMTK 0.00
- COCP 0.02
- Stochastic Oscillator
- SMTK 0.00
- COCP 56.10
About SMTK SMARTKEM INC
SmartKem Inc focuses on the design, development, industrialization, and technology transfer of low-temperature, solution-deposited organic semiconductors for transistor backplanes. The company's semiconductor platform can be used in a number of applications including mini-LED displays, AMOLED displays, fingerprint sensors, and logic circuits. The company derives revenue from the sale of TRUFLEX inks and demonstration products.
About COCP Cocrystal Pharma Inc.
Cocrystal Pharma Inc is a biotechnology company discovering and developing novel antiviral therapeutics that target the replication machinery of influenza viruses, hepatitis C viruses, and noroviruses. It employs structure-based technologies and Nobel Prize-winning expertise to create first and in-class antiviral drugs. It is developing CC-31244, an investigational, oral, broad-spectrum replication inhibitor called a non-nucleoside inhibitor (NNI).